Myeloma therapy: pursuing the plasma cell

Por Cavenagh, J
Publicado em 2010

Nasopharyngeal Sepsis in Cases of Mental Disorder

Por Cavenagh, J. B.
Publicado em 1937

WHAT IS A “DISEASED” TONSIL?

Por Cavenagh, J. B.
Publicado em 1923

MUCOCELE OF THE FRONTAL SINUS

Por Cavenagh, J. B.
Publicado em 1922

Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.

Por Cavenagh, J. D., Colvin, B. T.
Publicado em 1996

Cavernous Sinus Thrombosis: A Study of the Cases of Recovery

Por Cavenagh, J. B., Oxon, B.M.
Publicado em 1936

Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia

Por Dalley, C D, Lister, T A, Cavenagh, J D, Rohatiner, A Z S
Publicado em 2001

Haematological validation of a computer-based bone marrow reporting system.

Por Nguyen, D T, Diamond, L W, Cavenagh, J D, Parameswaran, R, Amess, J A
Publicado em 1997

Optimising testing for phospholipid antibodies

Por Helbert, M, Bodger, S, Cavenagh, J, D'Cruz, D, Thomas, J, MacCallum, P
Publicado em 2001

Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib

Por Ishii, T, Seike, T, Nakashima, T, Juliger, S, Maharaj, L, Soga, S, Akinaga, S, Cavenagh, J, Joel, S, Shiotsu, Y
Publicado em 2012

Benign monoclonal expansion of CD8+ lymphocytes in HIV infection

Por Smith, P., Cavenagh, J., Milne, T., Howe, D., Wilkes, S., Sinnott, P., Forster, G., Helbert, M.
Publicado em 2000

Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine.

Por Schneider, J J, Ravenscroft, P J, Cavenagh, J D, Brown, A M, Bradley, J P
Publicado em 1992

The risk of antimalarials in patients with renal failure

Por Thorogood, N, Atwal, S, Mills, W, Jenner, M, Lewis, D A, Cavenagh, J D, Agrawal, S G
Publicado em 2007

Guillain Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia

Por Kaya, B, Davies, C E, Oakervee, H E, Silver, N C, Gawler, J, Cavenagh, J D
Publicado em 2005

Mullins’ syndrome: a new gammopathy-related autoinflammatory syndrome resistant to anakinra

Por Longhurst, H.J., Yong, P.F.K., Manson, A.L., Cavenagh, J.D., Grigoriadou, S., Buckland, M.S.
Publicado no QJM (2015)

Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies

Por Yong, K, Cavet, J, Johnson, P, Morgan, G, Williams, C, Nakashima, D, Akinaga, S, Oakervee, H, Cavenagh, J
Publicado no Br J Cancer (2016)

Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency

Por Longhurst, H J, O'Grady, C, Evans, G, De Lord, C, Hughes, A, Cavenagh, J, Helbert, M R
Publicado em 2002

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()

Por Dennis, M., Culligan, D., Karamitros, D., Vyas, P., Johnson, P., Russell, N.H., Cavenagh, J., Szubert, A., Hartley, S., Brown, J., Bowen, D.
Publicado em 2013

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

Por Cavenagh, J, Oakervee, H, Baetiong-Caguioa, P, Davies, F, Gharibo, M, Rabin, N, Kurman, M, Novak, B, Shiraishi, N, Nakashima, D, Akinaga, S, Yong, K
Publicado no Br J Cancer (2017)